According to the thresholds for cost effectiveness set forth by the Commission for Macroeconomics and Health, the cost per DALY of an intervention needs to be below the GDP per capita of a country to be considered highly cost-effective.
Healthcare organizations have a hierarchical structure, which may create conflicts between the goals for cost-effectiveness set up at different levels.
As HIV/AIDS services are rapidly scaled up, determining the cost of specific HIV/AIDS interventions is critical in order to evaluate their cost-effectiveness, set program priorities, and budget for further scale-up [ 2].
Based on modelling of other interventions for smoking cessation in pregnancy, it is most likely that these schemes fall within the acceptable range of cost-effectiveness set by NICE [ 34].
In the cost-effectiveness setting, the INHB of an experimental treatment compared to a control is defined as INHB = (ε E - ε C ) - (γ E - γ C )/ λ where λ can be thought of as the maximum society is willing to pay for an incremental gain in health [ 20].
This analysis follows the standardised methodology on cost effectiveness analysis set forth by the WHO-CHOICE project 12 13 14 and builds on previous analyses of public health interventions to lower systolic blood pressure and cholesterol 15 and of tobacco use.
Yet he balances this with insight into care models aimed to improve cost effectiveness in the setting of better clinical outcomes.
Pharmaceutical manufacturers often charge much more for drugs in the United States than they charge for the same drugs in Britain, where they know that a higher price would put the drug outside the cost-effectiveness limits set by NICE.
The threshold for cost-effectiveness was set at €50,000 (451,675 SEK) throughout these results.
Therefore, separate sensitivity analyses may be performed on the cost-effectiveness data set and the results may be reported for costs at patient level.
PHARMAC, with the assistance of independent medical experts on the Pharmacology and Therapeutics Advisory Committee ("PTAC") and its specialist sub-committees, manages, on cost-effectiveness grounds set out in guidelines, a Federal formulary, known as the Pharmaceutical Schedule.
